Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 3838646, 6 pages
Research Article

Prenatal and Childhood Growth, Chemerin Concentrations, and Metabolic Health in Adult Life

1National Institute for Health and Welfare, Department of Chronic Disease Prevention, 00271 Helsinki, Finland
2Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, 00014 Helsinki, Finland
3Folkhälsan Research Centre, 00250 Helsinki, Finland
4Institute of Biomedicine, Exercise Medicine, University of Eastern Finland, 70211 Kuopio, Finland
5MRC Lifecourse Epidemiology Unit (University of Southampton), Southampton General Hospital, Southampton SO16 6YD, UK

Received 10 October 2015; Revised 5 December 2015; Accepted 16 December 2015

Academic Editor: Kristin Eckardt

Copyright © 2016 Johan G. Eriksson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Several noncommunicable diseases have their origins in early developmental phases. One factor possibly explaining the association between early growth and later health could be adipocyte function. The objective of this study was to assess the association between the adipocytokine chemerin and early growth and later health. 1074 participants from Helsinki Birth Cohort Study born 1934–1944 with information on prenatal and childhood growth participated. Metabolic outcomes include glucose tolerance, adiposity, and chemerin concentration. Mean chemerin concentrations were 5.0 ng/mL higher in women than in men (95% CI 2.7 to 7.2, ). The strongest correlate of chemerin concentration was adult waist circumference and body fat percentage (, and , , resp.). After adjustment for body fat percentage, chemerin concentration was 5.4 ng/mL lower in subjects with type 2 diabetes than in those with normal glucose tolerance (−0.2 to 10.9, ). It was 3.0 ng/mL higher in those with metabolic syndrome than in those without (0.6 to 5.3, ). No measure of early growth was associated with chemerin concentration. Our findings do not support a role for chemerin in linking early growth with later metabolic health.